U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07936422) titled 'A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer Patients' on Oct. 20.
Brief Summary: MOST Express is a multicenter, open-label, personalized medicine, tumor agnostic platform phase II evaluating the anti-tumor activity of antibody-based therapies in advanced/metastatic cancer patients. Patients will be assigned to a treatment cohort based on molecular alterations/characteristics detected on tumor sample (from primary tumor or metastatic lesion). Our proposal is to develop a large adaptive personalized medicine platform program with multiple cohorts defined by molecular alterations / charac...